Clinical Guidelines for Transplant Medications
2021
MEDICATION GUIDELINES FOR
SOLID ORGAN TRANSPLANTS
Revised May 2021v2
?
Tacrolimus target level update
?
Hep B section update
?
Management guidelines section
AMB.03.007 Rev11 Eff Date: 13-May-21
_______________________________________________________________________
Table of Contents (Click links to drug sections)
Page
1. Introduction
3
2. Anti-lymphocyte polyclonal antibody (ATG)
5
3. Azathioprine
10
4. Basiliximab
13
5. Cyclosporine
18
6. Erythropoiesis-Stimulating Agents (Darbepoetin/Erythropoietin)
30
7. Filgrastim (G-CSF)
35
8. Hepatitis B Antiviral Agents (Entecavir, Tenofovir, Lamivudine)
39
9. Letermovir
10.Mycophenolic Acids: Mycophenolate Mofetil and Mycophenolate
Sodium
45
48
11.Prednisone
57
12.Sirolimus
62
13.Tacrolimus
76
14.Valganciclovir
88
15. Management Guidelines (BK virus; dental prophylaxis; Herpes
simplex virus; immunization; Pneumocystis jiroveci (PJP); posttransplant diarrhea; post-transplant neutropenia)
102
16. Appendices (sirolimus; ESA and filgrastim request forms)
115
Table of Contents
________________________________________________________________________
Introduction
Patients who undergo solid organ transplant require lifelong immunosuppression to prevent organ
rejection. In organ transplantation, the ideal form of immunosuppression is to induce donor specific
tolerance without impairing the host defences or increasing the susceptibility to infection from all
types of organisms.
The most common immunosuppressants prescribed for solid organ transplant recipients are:
?
?
?
?
?
?
?
Calcineurin Inhibitors:
Cyclosporine
Tacrolimus
Mycophenolic Acids:
Mycophenolate Mofetil
Mycophenolate Sodium
Azathioprine
Sirolimus
Prednisone
Basiliximab
Anti-thymocyte Globulin
Each of these drugs has its own adverse effect and toxicity profile that may result in serious
morbidity or mortality. Careful management of these complications by the patient and the
transplant team is critical to transplant success.
BC Transplant funds the following outpatient immunosuppressants for solid organ and pancreatic
islet cell transplant recipients who have BC Medical Services Plan coverage and are registered with
BC Transplant, when the guidelines are followed:
Outpatient Immunosuppression:
? Calcineurin Inhibitors:
Cyclosporine
Tacrolimus IMMEDIATE Release
Tacrolimus EXTENDED Release
? Mycophenolic Acids:
Mycophenolate Mofetil
Mycophenolate Sodium
? Azathioprine
? Sirolimus
? Prednisone
Clinical Guidelines for Transplant Medications
Page 3
Table of Contents
________________________________________________________________________
Inpatient Immunosuppression
BC Transplant funds the inpatient immunosuppressant basiliximab and entanercept for pancreatic
islet cell transplant when the guidelines are followed.
Special Outpatient Medications Required to Maintain Transplant
In addition to immunosuppressants, solid organ transplant recipients often require other outpatient
medications which are needed to maintain the integrity of the transplant and are very important in
a patients¡¯ medication regimen. BC Transplant covers the cost of the following medications if the
guidelines are met:
Erythropoiesis - Stimulating Agents:
? Erythropoietin
? Darbepoetin
Anti-Viral Agents:
? Valganciclovir
? Lamivudine
? Adefovir
? Tenofovir
? Entecavir
? Leflunomide
Clinical Guidelines for Transplant Medications
Page 4
Table of Contents
________________________________________________________________________
Anti-lymphocyte polyclonal antibody (ATG)
INTRODUCTION
Anti-thymocyte globulin (ATG) is a pasteurized solution of rabbit-derived polyclonal IgG antibodies directed
against human T cells, produced by immunization of rabbits with human lymphocytes.
This monograph will focus on its use in solid organ transplants. ATG is funded by the inpatient pharmacy
drug budget and not covered by BC Transplant.
MECHANISM OF ACTION
ATG is potent immunosuppressant and immunomodulator whose mechanisms of action are not fully
understood.
The mixture of antibodies recognize key receptors on T-cells, resulting in complement-dependent T-cell lysis
and opsonisation of T-cells with subsequent phagocytosis by macrophages. Thymopoiesis is also impaired,
resulting in a decrease in the number of newly formed T-cells. This causes a substantial drop in the number
of circulating T-cells, hence reducing the risk of organ rejection.
The usual magnitude is a greater than 90% reduction in the number of circulating T-cells. The duration of
lymphopenia lasts around 3 months for most patients, though some have had sustained lymphopenia for
over 1 year post-ATG.
ATG has shown benefits for patients at high risk of delayed graft function (DGF), potentially due to reducing
ischemia-reperfusion injury by inflammatory mediators produced from T-lymphocytes.
PHARMACOKINETICS
Absorption / Onset:
T-cell depletion is usually noted within 1 day of the first ATG dose.
Distribution:
The volume of distribution of ATG is approximately 2 times plasma volume.
Distribution into breast milk is unknown, though other immunoglobulins do enter breast milk.
Metabolism:
Likely removed via opsonisation by the reticuloendothelial system if bound to T-cells, or via human
antibody production.
Elimination:
Plasma half-life is variable (1.5 to 30 days5, usually 2 to 3 days).
ATG remains active for days to weeks post-treatment.
The primary route of elimination is via cellular uptake with subsequent proteolytic degradation.
Hence, no dosage adjustment is required in renal or hepatic impairment.
Clinical Guidelines for Transplant Medications
Page 5
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- clinical guidelines for conjunctivitis
- clinical practice guidelines for conjunctivitis
- clinical guidelines for chf treatment
- clinical guidelines for allergic conjunctivitis
- clinical guidelines for cad
- clinical guidelines for myocardial infarction
- clinical guidelines for heart failure
- clinical guidelines for osteopenia
- clinical practice guidelines for osteoporosis
- clinical practice guidelines for influenza
- clinical guidelines for chest pain
- clinical guidelines for pain management